New review assesses how tavapadon and D1/D5 dopamine therapies help movement in Parkinson's

For decades, many standard therapies designed to boost dopamine have focused primarily on stimulating what scientists call D2 and D3 dopamine receptors in the brain. While these treatments can help ease movement difficulties, they often bring unwanted side effects, particularly extreme daytime sleepiness and impulse control behaviours such as compulsive shopping or gambling. A newer class of medications known as selective D1 and D5 dopamine receptor partial agonists, with the drug tavapadon leading the way, was created with the hope of smoothing out movement while sidestepping those troublesome behavioural side effects. A comprehensive systematic review and meta-analysis published in Neurological Sciences by Dr Ahmad Akhtar Rashid and colleagues offers the first complete quantitative look at how well these new drugs actually perform. The researchers brought together data from seven randomised, double-blind, placebo-controlled trials involving 1,540 participants, with five of these studies providing detailed data for a combined statistical analysis. To assess the quality and reliability of the evidence, the team used the standard GRADE framework, which rates findings from very low to high certainty. When looking at physical movement, the findings show genuine, measurable benefits. In people who are in the earlier stages of the condition and taking the medication on its own, tavapadon improved daily living and movement scores on the standard Parkinson's assessment scale by an average of 10.55 points compared with a dummy pill. For people already taking levodopa who experience daily fluctuations, adding tavapadon increased good ON time by an average of 1.09 hours each day. This means participants gained more than an hour of smoothly controlled movement without troublesome involuntary jerks or spasms. The certainty of the evidence for these motor improvements was rated as moderate. The safety profile, however, shows that the drug still brings several familiar challenges. Participants taking tavapadon were more likely to experience overall side effects, most notably nausea, which occurred more than six times as often as in the placebo group, and dizziness, which was three times more common. Because of these issues, people on tavapadon were nearly three times as likely to stop taking the medication during the trials. On a reassuring note, serious medical complications were not significantly increased. The biggest question mark surrounds whether this new drug class truly avoids the behavioural side effects seen with older dopamine therapies. The review found that evidence regarding impulse control issues and daytime drowsiness remains at very low certainty. Across all studies, impulse control difficulties were rare, with only nine total events recorded in a single trial. More importantly, none of the clinical trials tested tavapadon head to head against existing dopamine agonists, and no trial lasted longer than 27 weeks. The review confirms that selective D1 and D5 treatments like tavapadon provide meaningful improvements in movement and help extend good daily hours for people managing motor fluctuations. At the same time, whether they truly deliver a safer long-term profile for mood and behaviour will require longer studies that compare them directly with the treatments already in use.